Metabolic research — investigational
Retatrutide 5 mg
An investigational triple receptor agonist under clinical development. It is NOT approved for public use anywhere and should be regarded strictly as a research and clinical-trial compound.
Investigational compound
Retatrutide is investigational and is not approved for public use. It is not authorised for supply to the public outside an approved clinical trial. This page is informational only.
What it is
Retatrutide is an investigational multi-receptor agonist being evaluated in sponsor-run clinical trials. It is not an approved medicine in South Africa or elsewhere, and it is not authorised for public use or supply outside of an approved clinical trial.
Mechanism being studied
Development programmes describe combined agonism at GIP, GLP-1 and glucagon receptors, pathways involved in appetite regulation and energy metabolism. Mechanistic descriptions here are informational only.
Human evidence
Phase 2 trial results have been published in peer-reviewed journals. Late-stage trials are ongoing. Investigational results do not constitute approval, and long-term safety data are not complete.
Safety considerations
Because retatrutide is investigational, its full safety profile is not established. Trial reports describe gastrointestinal adverse events among others. Unregistered copies sold outside licensed channels carry additional risks of incorrect identity, potency, sterility and contamination. Safety information for this compound is incomplete outside of controlled settings. Reported considerations in the literature include injection-site reactions, unknown long-term effects, product-quality and sterility risks with unregistered preparations, and unpredictable interactions with existing medicines or conditions. Any consideration of use belongs with a registered healthcare professional who can assess the individual clinical picture.
Regulatory status
Investigational. Not approved by SAHPRA, FDA, EMA or other major regulators for public use. Supply to the public outside an authorised clinical trial is not lawful in most jurisdictions, including South Africa.
Certificate of analysis
Third-party analytical documentation for this compound is published for transparency and professional review. It confirms identity and purity of tested material only, and is not a marketing authorisation, a registration, or a recommendation for use.
View certificate (PDF)Key references
- Published phase 2 clinical trial reports in peer-reviewed journals.
- ClinicalTrials.gov registrations for retatrutide programmes.
- SAHPRA — warnings regarding unregistered injectable weight-related products.
References are provided as reading directions for professionals. They do not constitute endorsement of any use.
Information only — availability subject to applicable law, prescription/authorisation, and licensed healthcare/pharmacy channels. Nothing on this page is an offer to sell, and no dosing or self-administration guidance is provided.
South Africa — compliance notice
SAHPRA has publicly warned about unregistered peptide products being marketed to the South African public. In general, products intended to diagnose, treat, or otherwise alter bodily functions require registration or authorisation before they may lawfully be sold. ELLIVON BIOSCIENCES publishes reference information only and directs all clinical questions to registered healthcare professionals and licensed pharmacy channels.